We acknowledge that we cannot conclude that PRDX1 is sufficiently sensitive and specific to be considered as a screening biomarker for EOC based on our limited validation sample cohort, however, that it is detectable and elevated in ovarian cancer patient serum compared matched benign controls provides further supporting evidence to the hypothesis that protein candidates discovered in TIF are likely to be present in peripheral circulation. This evidence concerns the gene PRDX1 and ovarian carcinoma.